Aleeto in Acute ISchemic StrokeA RandomISed Controlled Clinical Trial
Status:
RECRUITING
Trial end date:
2026-01-31
Target enrollment:
Participant gender:
Summary
This study is a prospective, double-blind, 1:1:1 randomized controlled study aimed at evaluating the efficacy and safety of Aleeto treatment compared to placebo in improving the NIHSS score at 14 days in patients with moderate to severe acute ischemic stroke. It also aims to explore the neuroprotective effects of Aleeto in moderate to severe acute ischemic stroke and provide data support and evidence for future clinical trials and evidence-based medicine.